Skip to main content
SpringerLink
Log in

Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Introduction

To investigate the potential prognostic value of image analysis of pelvic bone metastasis in newly diagnosed prostate cancer patients.

Methods

Data from 69 patients with both bone scintigraphy and pelvic CT images were selected for this analysis. Open source software (3D Slicer version 4.8.1.) was used for image analysis. Metastatic pelvic bone lesions were manually contoured, and radiomic features were extracted. As risk factors for overall survival (OS) and cause-specific survival (CSS), 105 radiomic features and clinical risk factors including age, initial prostate-specific antigen, Gleason score, TNM stage, lactate dehydrogenase (LDH), hemoglobin (Hb), alkaline phosphatase, extent of disease, visceral metastases, and radiotherapy were assessed by uni- and multivariate analyses.

Results

Median follow-up was 41 months (range 0–157 months). Five-year overall survival and cause-specific survival rate were 37.9% and 43.5%, respectively. After multivariate analysis, LDH, Hb, and “maximum 2D diameter” defined as maximum tumor size in the axial plane were detected as risk factors for OS. Gleason sum, LDH, and maximum 2D diameter were detected as risk factors for CSS.

Conclusion

Maximum 2D diameter was detected as a significant prognostic factor for metastatic prostate cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available.

Abbreviations

OS:

Overall survival

CSS:

Cause-specific survival

LDH:

Lactate dehydrogenase

Hb:

Hemoglobin

EOD:

Extent of disease

ALP:

Alkaline phosphatase

References

  1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.

    Article  CAS  Google Scholar 

  2. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.

    Article  Google Scholar 

  3. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.

    Article  CAS  Google Scholar 

  4. Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68(2):325–34.

    Article  Google Scholar 

  5. Koizumi M, Motegi K, Koyama M, Terauchi T, Yuasa T, Yonese J. Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups. Ann Nucl Med. 2017;31(7):521–8.

    Article  Google Scholar 

  6. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195–202.

    Article  CAS  Google Scholar 

  7. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112(1):138–49.

    Article  CAS  Google Scholar 

  8. Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Japan

    Toyokazu Hayakawa, Shogo Kawakami & Hiromichi Ishiyama

  2. Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

    Ken-ichi Tabata, Hideyasu Tsumura & Masatsugu Iwamura

  3. Kitasato University School of Allied Health Sciences, Sagamihara, Kanagawa, Japan

    Takeo Katakura, Masatoshi Hashimoto, Yusuke Watanabe & Tomoyuki Hasegawa

Authors
  1. Toyokazu Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken-ichi Tabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hideyasu Tsumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shogo Kawakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takeo Katakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masatoshi Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yusuke Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masatsugu Iwamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoyuki Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiromichi Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TH and HI drafted the manuscript. TH, KT, HT, SK, TK, MH, YW, and HI participated in the design of the study. TH and HI performed the statistical analysis. MI and TH supervised the study. TH, KT, HT, SK, TK, MH, YW, and HI collected medical information about this study.

Corresponding author

Correspondence to Hiromichi Ishiyama.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval and consent to participate

This study was approved by the institutional review board of Kitasato University School of Medicine (B17-245). No consent was required as this study used anonymized registry data.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hayakawa, T., Tabata, Ki., Tsumura, H. et al. Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients. Jpn J Radiol 38, 993–996 (2020). https://doi.org/10.1007/s11604-020-01004-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-020-01004-5

Keywords

Search

Navigation